title: KIT in ovarian carcinoma: disillusion about a potential therapeutic target.
authors.forename: Gad
authors.initials: G
authors.lastname: Singer
authors.forename: Peter
authors.initials: P
authors.lastname: Schraml
authors.forename: Christopher
authors.initials: C
authors.lastname: Belgard
authors.forename: Anna
authors.initials: A
authors.lastname: Raggi
authors.forename: Stephan
authors.initials: S
authors.lastname: Dirnhofer
authors.forename: Philip
authors.initials: P
authors.lastname: Went
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Mihatsch
authors.forename: Holger
authors.initials: H
authors.lastname: Moch
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D009154:Mutation; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use; D016133:Polymerase Chain Reaction / Q000379:methods; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases